Core Insights - Cryoport, Inc. has introduced the Cryoport Express® Cryogenic HV3 Shipping System, enhancing patient access to critical therapies and showcasing it at Phacilitate's Advanced Therapies Week in Dallas [1][5] Product Features - The HV3 shipping system offers unparalleled protection for biologics, eliminating the need for palletization and allowing transport on narrow-bodied aircraft, thus increasing shipping lanes and improving patient access [2][3] - It provides enhanced payload protection, resilience during transport, and improved storage efficiency through stackable design, while maintaining temperature stability at -150°C or lower [3][4] - The system is designed for mobility with robust wheels and a front-facing handle, facilitating efficient handling at various sites, including point-of-care and manufacturing locations [4][6] Company Commitment - The CEO of Cryoport emphasized the company's commitment to addressing industry challenges and improving patient outcomes through innovative solutions like the HV3 [5] - The Chief Product Development Officer highlighted the user-centric design of the HV3, aimed at overcoming logistical challenges in transporting advanced therapies globally [6] Company Overview - Cryoport, Inc. is a global leader in supply chain solutions for life sciences, focusing on cell and gene therapies, and offers a wide range of services to ensure compliance and efficiency in the supply chain [7][8]

Core Insights - Moffitt Cancer Center and Cryoport, Inc. have announced a strategic collaboration to provide state-of-the-art biorepository services through Cryoport's CRYOGENE unit, enhancing Moffitt's capabilities in cell and gene therapies [1][2][3] Company Overview - Moffitt Cancer Center is a National Cancer Institute-designated comprehensive cancer center focused on cancer prevention and treatment, recognized for its scientific excellence and multidisciplinary research [9] - Cryoport, Inc. is a global leader in supply chain solutions for the life sciences industry, specializing in biostorage and logistics services for cell and gene therapies [10][11] Collaboration Details - The collaboration aims to transform Moffitt's Speros campus into a global epicenter for innovation in various therapies, including cell and gene therapies, immunotherapies, and radiopharmaceuticals [2][3][4] - CRYOGENE will provide advanced biostorage technologies and logistics services, supporting both patient treatments and medical research at Moffitt [3][4] Market Potential - The cell and gene therapy industry is projected to exceed $97 billion by 2033, with a compound annual growth rate of 18.3% from 2024 to 2033, highlighting the growing demand for biorepository services [3] Infrastructure Development - The CRYOGENE facility will be integrated into the initial phase of the Speros campus development, located next to Moffitt's Discovery & Innovation Center, which spans 250,000 square feet [2][4] - Speros aims to create a comprehensive ecosystem for life sciences, focusing on critical activities such as drug discovery, artificial intelligence, and biotech [5][6]

Core Insights - Cryoport, Inc. announced that MVE Biological Solutions has registered all three of its manufacturing facilities with the FDA, enhancing its compliance and credibility in the life sciences sector [1][2][3] Company Overview - Cryoport, Inc. is a global leader in supply chain solutions for cell and gene therapies, providing a wide range of services including temperature-controlled packaging and bio-logistics [4] - MVE Biological Solutions is recognized as the leading manufacturer of cryogenic storage and shipping devices, with over 60 years of experience in the industry [6] Regulatory Compliance - MVE adheres to stringent FDA requirements, including 21 CFR Part 820 and Good Manufacturing Practices (GMP), in addition to holding an ISO 13485 certification [2][3] - The FDA registration and product listing signify MVE's commitment to meeting high global regulatory standards [2][3] Manufacturing Facilities - MVE's manufacturing facilities are located in Ball Ground, Georgia; New Prague, Minnesota; and Chengdu, China, with products distributed globally in 88 countries [1][7] Commitment to Quality - The CEO of Cryoport emphasized the company's dedication to delivering high-quality supply chain solutions and bringing lifesaving therapies to patients [3]

Group 1 - The article expresses a negative outlook on Cryoport (NASDAQ: CYRX), labeling it as one of the worst long-term investment opportunities in the market [1] - Crude Value Insights focuses on cash flow and companies that generate it, emphasizing value and growth prospects in the oil and natural gas sector [1] Group 2 - Subscribers to Crude Value Insights gain access to a 50+ stock model account and in-depth cash flow analyses of exploration and production (E&P) firms [2] - The service includes live chat discussions about the oil and gas sector, enhancing community engagement and information sharing [2] - A promotional offer is available for a two-week free trial, encouraging new sign-ups to explore the oil and gas investment opportunities [3]

Core Insights - Cryoport, Inc. has opened a new IntegriCell facility in Villers-le-Bouillet, Belgium, aimed at supporting clinical and commercial cell-based therapy programs through advanced cryopreservation solutions for leukapheresis materials [1][3][4] Group 1: Facility Overview - The IntegriCell facility spans approximately 1,300 square meters (about 13,400 square feet) and is GMP-compliant, enhancing Cryoport's capabilities in cryogenic preservation methods for leukapheresis materials [3] - The facility is designed to cryopreserve over 1,100 leukapheresis products annually, ensuring a reliable supply of high-quality, manufacture-ready cryopreserved leukopaks [3][4] Group 2: Strategic Importance - This facility serves as Cryoport Systems' European Center of Excellence, facilitating the transfer of optimized cryopreservation processes to other Cryoport locations, thereby ensuring consistent quality across various clinical and commercial programs [3][4] - The opening of the Belgium facility extends Cryoport's global reach and enhances its ability to deliver standardized cryopreservation solutions, which is critical for the cell therapy community [4] Group 3: Company Background - Cryoport, Inc. is recognized as a global leader in supply chain solutions for the life sciences sector, particularly focusing on cell and gene therapies [5] - The company operates over 50 global locations across 17 countries, providing a broad array of supply chain solutions, including temperature-controlled packaging and specialized bio-logistics services [6]

Financial Data and Key Metrics Changes - The Life Sciences Services business experienced a 9% growth in Q3 2024, with BioStorage and BioServices revenue increasing over 12% year-over-year [9] - The company maintained its full-year revenue guidance of $225 million to $235 million, anticipating continued growth in Life Science Services despite ongoing softness in the Life Sciences Product business [10] - Gross margin improved to 46% for the Life Science Services business, with adjusted EBITDA showing positive cash flow through the quarter [11][45] Business Line Data and Key Metrics Changes - BioServices revenue was just under $4 million, up 12%, indicating solid improvement and consistent increases in BioServices revenue outpacing the overall services business [34] - The MVE Biological Solutions business faced uneven market recovery, with weaker cryogenic freezer demand in North America and EMEA, but a pickup in order flow from APAC [31] - CRYOGENE's biorepository operations in San Antonio successfully onboarded its first major client, contributing to growth in the national cord blood market [14] Market Data and Key Metrics Changes - The company supported a total of 691 global clinical trials as of September 30, a net increase of 21 clinical trials over the previous year, with 79 of these in Phase III [19] - Biopharma market funding decreased sequentially in Q3 2024, totaling about $16 billion compared to $43 billion in Q1 and $23 billion in Q2, but year-to-date aggregate funding remains notably above 2023 and 2022 levels [26] Company Strategy and Development Direction - The company is focused on executing cost reduction and realignment strategies to achieve sustainable profitability, with expectations of returning to positive adjusted EBITDA during 2025 [11][20] - The launch of the IntegriCell cryopreservation solution aims to optimize the supply chain for cell-based therapies, enhancing service offerings [13] - The company is strategically positioned to leverage anticipated long-term growth in life sciences and the high-growth cell and gene therapy markets [21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing macro and sector-specific challenges impacting life science tools companies but remains optimistic about long-term growth trajectories [20] - The company expects to see a strong step-up in Q4 2024, driven by the ramp-up of recently launched therapies and increased clinical trial activity [51][64] - Management indicated that the demand for MVE products is expected to remain depressed for the year, but the business remains profitable with positive cash flow [32][42] Other Important Information - The company has initiated actions expected to generate over $20 million in annualized cost savings, with improvements in gross margin and cash flow already observed [43][45] - The first manufactured units of the HV-3 shippers are undergoing final qualification and quality checks, with market availability expected by the end of the year [56] Q&A Session Summary Question: Clinical trial service business performance - Management noted that label expansions take about six to twelve months to impact operations, with several projects contributing positively [23][24] Question: MVE product line performance - Demand for cryogenic freezers has been weaker in North America and EMEA, but order flow from APAC is improving [31] Question: BioStorage business updates - BioServices revenue continues to increase, and the IntegriCell launch is progressing well with contracts signed [34][35] Question: 2025 market demand expectations - Management expects modest revenue changes for MVE and anticipates a strong step-up in services revenue due to ongoing clinical trial support [55][62] Question: Commercial revenue outlook - Management is confident in the long-term growth of commercial revenue, supported by multiple therapy approvals and ongoing clinical trials [60][63]

Q3 2024 Earnings Call November 7, 2024 Forward Looking Statements Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-ter ...

Financial Performance - CryoPort, Inc. reported a quarterly loss of $0.02 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.25, representing an earnings surprise of 92% [1] - The company posted revenues of $56.66 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 2.52%, but showing a slight increase from $56.16 million year-over-year [2] - Over the last four quarters, CryoPort has surpassed consensus EPS estimates two times, but has not beaten consensus revenue estimates during the same period [2] Stock Performance - CryoPort shares have declined approximately 48.2% since the beginning of the year, contrasting with the S&P 500's gain of 24.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.22 on revenues of $59.54 million, and for the current fiscal year, it is -$1.68 on revenues of $229.79 million [7] Industry Outlook - The Transportation - Services industry, to which CryoPort belongs, is currently ranked in the bottom 18% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of CryoPort's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPOR ...

Exhibit 99.1 Cryoport Reports Third Quarter 2024 Financial Results § Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% yearover-year § Supported a record total of 691 global clinical trials as of September 30, 2024 § Company reaf irmed full year 2024 revenue guidance of $225 to $235 million NASHVILLE, Tennessee, November 7, 2024, - Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, tod ...